FDA-Approved Peptides List: Which Peptides Are Actually Approved (2026)

When people say "peptides," they often mean two very different things: a small group of FDA-approved prescription drugs that have passed real clinical trials, and a much larger pool of research compounds sold online that the FDA has never approved for human use. Confusing the two is how people end up trusting a marketing claim that no regulator ever signed off on. This guide draws a hard line between them, names the peptides that actually carry FDA approval, and grades the evidence honestly so you know what's proven and what isn't.

What "FDA approved" actually means for a peptide

A peptide is just a short chain of amino acids, smaller than a full protein but built from the same parts. Insulin is a peptide. So is the GLP-1 in Ozempic. Roughly 100 peptide drugs have been approved by the FDA since insulin first reached patients in the 1920s, and that number keeps growing as the peptide therapeutics field expands.

"FDA approved" is a specific legal status. It means a company submitted a New Drug Application, ran controlled human trials, and the agency reviewed the safety and effectiveness data for a named condition. Approval is always tied to that condition, called an indication. A peptide approved to treat HIV-related fat buildup is not "FDA approved for anti-aging" just because it gets used that way off-label.

This matters because most peptides marketed to consumers fall into a different bucket. They were never approved. Some are sold as "research chemicals" labeled not for human use. Others are mixed by compounding pharmacies, which is a separate legal pathway with far less oversight than full approval. The rest of this article keeps those categories straight.

One more point on language. People use "FDA approved" loosely, and marketers exploit that. A peptide can be "legal to research," "available through a compounding pharmacy," or "sold as a supplement ingredient" without being approved as a drug. None of those phrases mean the FDA reviewed it for safety and effectiveness. Approval is a high bar. Most peptides never clear it, and many never even try.

How peptides work in the body

Peptides are bigger than typical small-molecule pills but smaller than antibodies, usually somewhere between 500 and 5,000 daltons in weight. That middle size is part of why they're useful. They're large enough to bind their target precisely, which tends to mean fewer off-target effects, but small enough to be manufactured at scale.

Most therapeutic peptides work by acting on receptors on the surface of cells. A peptide either switches a receptor on (an agonist) or blocks it (an antagonist). GLP-1 drugs are agonists: they activate the same receptor your gut hormones use, which slows stomach emptying and dials down appetite. GnRH analogs used in prostate cancer can do the opposite over time, shutting a signaling pathway down. The mechanism is usually well understood for approved peptides because the approval process demands it.

The flip side is fragility. Most peptides break down in the stomach, which is why so many are injected rather than swallowed. Getting a peptide to survive digestion is a genuine engineering problem — Rybelsus, the oral semaglutide tablet, needed a special absorption enhancer to work at all. When you see an unapproved peptide sold as an oral capsule or a nasal spray with big claims, that's a reason for more skepticism, not less.

The short answer: how many peptides are actually approved

There is no single tidy "peptide list" the FDA publishes, because peptides are scattered across drug classes — diabetes, bone, cancer, HIV, women's health, and more. But the count of distinct approved peptide drugs sits around 100 across all of medicine. The ones consumers actually ask about cluster into a handful of categories.

Here is the honest split. The table below shows widely discussed peptides and their real status as of mid-2026.

Peptide	Brand name(s)	FDA approved?	Approved use	Evidence strength
Semaglutide	Ozempic, Wegovy, Rybelsus	Yes	Type 2 diabetes; chronic weight management	Strong
Tirzepatide	Mounjaro, Zepbound	Yes	Type 2 diabetes; chronic weight management	Strong
Liraglutide	Victoza, Saxenda	Yes	Type 2 diabetes; weight management	Strong
Tesamorelin	Egrifta, Egrifta SV	Yes	Excess abdominal fat in HIV lipodystrophy	Moderate
Bremelanotide	Vyleesi	Yes	Premenopausal hypoactive sexual desire disorder	Moderate (modest effect)
Insulin (analogs)	Many	Yes	Diabetes	Strong
Sermorelin	(formerly Geref)	No active approval	Withdrawn from market	Weak/dated
BPC-157	None	No	None	Weak (mostly animal)
TB-500 / thymosin beta-4	None	No	None	Weak (mostly animal)
Ipamorelin, CJC-1295	None	No	None	Weak (limited human data)
Melanotan II	None	No	None	Weak; safety concerns

The pattern is clear. The peptides with strong evidence are nearly all FDA approved. The peptides marketed hardest in the wellness world — BPC-157, TB-500, the growth-hormone secretagogues — are not approved and lean almost entirely on animal studies.

The approved peptides, one by one

GLP-1 and dual-agonist peptides (semaglutide, tirzepatide, liraglutide)

These are the peptides that changed medicine in the last few years, and they have the strongest evidence of anything on this list. They mimic gut hormones that control blood sugar and appetite.

Semaglutide is sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management. In the STEP-1 trial, adults with overweight or obesity who took weekly semaglutide plus lifestyle support lost a mean of 14.9% of body weight over 68 weeks, versus 2.4% on placebo — and 86% reached at least 5% loss (Wilding et al., NEJM 2021).

Tirzepatide (Mounjaro, Zepbound) hits two receptors, GLP-1 and GIP. In SURMOUNT-1, the 15 mg dose produced a mean 20.9% body-weight reduction over 72 weeks versus 3.1% on placebo (Jastreboff et al., NEJM 2022). That is among the largest weight-loss results ever seen from a drug.

Liraglutide (Victoza, Saxenda) is the older daily GLP-1. It works, but the weekly drugs above outperform it on weight, which is why it gets less attention now. It still has a role, especially where a shorter-acting drug is preferred.

What makes this class different from almost everything else in the peptide world is the depth of testing. These aren't single small studies. They're large, multi-thousand-patient, randomized, placebo-controlled trials, repeated across multiple programs, with regulators reviewing the raw data. Beyond weight, semaglutide has shown cardiovascular benefit in separate trials, which is why prescribers increasingly think of these drugs as more than cosmetic.

Evidence grade: strong. Large randomized trials, replicated, with hard outcomes. The trade-off is real side effects. Nausea and vomiting are common, especially during dose increases. There's also growing attention to muscle loss: when people lose weight fast, some of that loss is lean tissue, not just fat, which is why protein intake and resistance training matter on these drugs. They're prescription medications that belong under medical supervision, not something to source from a gray-market vendor.

Tesamorelin (Egrifta)

Tesamorelin is a modified version of growth-hormone-releasing hormone (GHRH). It tells the pituitary to release the body's own growth hormone in natural pulses. The FDA approved it in 2010 for one narrow use: reducing excess abdominal fat in people with HIV-associated lipodystrophy (FDA Egrifta label; trial summaries).

It's the only FDA-approved GHRH analog. That is exactly why it gets borrowed for off-label "anti-aging" and body-composition use. Important caveat: the approval is for HIV lipodystrophy, not for healthy adults chasing leaner abs. The fat reduction is real but tends to reverse when the drug stops.

Evidence grade: moderate. Solid for its approved population. Largely untested for the popular off-label uses.

Bremelanotide (Vyleesi)

Bremelanotide is a melanocortin receptor agonist approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It's injected before anticipated activity (FDA Vyleesi label; clinical evidence).

Be honest about the size of the effect. In trials, about 25% of women on bremelanotide reported a meaningful rise in desire score versus about 17% on placebo. That's a real but modest gap. Nausea is common. So it's approved and it works for some women — just don't expect dramatic results.

Evidence grade: moderate, with a small effect size.

Insulin and the older approved peptides

Insulin analogs are peptides too, and they're some of the most studied drugs in existence. Beyond insulin and the headline names above, the approved-peptide universe includes somatostatin analogs for certain tumors, GnRH analogs used in prostate cancer and fertility, calcitonin and teriparatide for bone, oxytocin in obstetrics, and several peptides used in heart and clotting medicine. The published reviews of the approved-peptide landscape catalog dozens of these across cardiovascular disease, HIV, cancer, and the central nervous system.

These aren't "wellness" peptides, but they're the bulk of what "FDA-approved peptides" actually means across medicine. The takeaway for a consumer: the real list of approved peptides is long, serious, and mostly made of drugs your doctor already knows by name. It does not include the recovery-and-longevity peptides sold on subscription. That gap is the whole story.

A quick word on the pipeline

A lot of attention right now goes to peptides that aren't approved yet but are deep in trials. Newer GLP-1-style drugs, oral versions, and triple-agonists are being tested, and some may reach approval in the next few years. "In late-stage trials" is genuinely more meaningful than "sold as a research chemical," because it means real human data exists and a regulator is watching. But it still isn't approval. A drug can look great in phase 2 and fail in phase 3. Treat pipeline buzz as a reason to watch, not a reason to buy from a vendor today.

The peptides that are NOT FDA approved

This is the section that matters most, because these are the peptides sold hardest online.

BPC-157

BPC-157 is marketed for tendon, gut, and joint healing. The honest read: nearly all the supporting evidence comes from rats and cell studies. There are essentially no published, well-controlled human trials proving it works or is safe long term. The FDA has never approved it, and in 2023 it was flagged as a Category 2 substance — meaning significant safety concerns for compounding (FDA 503A bulk substances guidance). The regulatory picture shifted again in 2026 and remains unsettled, but none of that movement amounts to approval.

Evidence grade: weak in humans. Promising animal data is not the same as proof.

TB-500 (thymosin beta-4)

Same story as BPC-157. Marketed for recovery and healing, supported mostly by animal and lab work, not approved, and also flagged for compounding-safety concerns. Often stacked with BPC-157 in marketing, which doubles the unknowns rather than the evidence.

Sermorelin, ipamorelin, CJC-1295 (growth-hormone secretagogues)

These tell the body to release more growth hormone, the same general idea as tesamorelin but without the approval and the trial data behind it. Sermorelin once held FDA approval (as Geref) but was withdrawn from the U.S. market. Withdrawal is not the same as a safety ban — products are pulled for business reasons too — but it means there's no actively approved sermorelin product you can point to today. Ipamorelin and CJC-1295 were never approved at all.

Human evidence for the anti-aging, muscle, and recovery claims around this group is thin. They reliably raise growth hormone in the short term; what that translates to in healthy adults over months or years, and at what risk, simply hasn't been established in the kind of trials approval requires.

Evidence grade: weak in humans for the marketed uses.

Melanotan II

Sold for tanning and libido. Not approved, and it carries genuine safety concerns including nausea, blood pressure changes, and reports of changing moles and new pigmented spots. Because some of those changes overlap with warning signs for skin cancer, this one earns extra caution. It is one of the clearer examples of a peptide where the marketing promise and the safety record point in opposite directions.

How peptides get sold when they're not approved

If these peptides aren't approved, how are people getting them? Three pathways, in rough order of legitimacy.

Pathway	What it is	Oversight level
FDA-approved drug	Full NDA, clinical trials, agency review	Highest
Compounding (503A/503B)	Pharmacy-mixed for specific patients	Moderate, variable
"Research chemical"	Sold online, labeled not for human use	None

Compounding is the gray zone most people don't understand. A compounding pharmacy can prepare a drug for a specific patient, but it must work from substances the FDA permits. For GLP-1s, that door is closing: in April 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need to compound them now that approved versions are widely available (FDA announcement, 2026). Translation: the era of cheap compounded GLP-1s is ending.

The "research chemical" pathway has no oversight at all. Products labeled "not for human use" skip purity testing, dosing standards, and safety review. What's in the vial may not match the label — wrong dose, wrong peptide, or contaminants from sloppy manufacturing. Independent testing of gray-market peptides has repeatedly turned up vials that don't match their labels. This is the riskiest way to buy a peptide, and the "not for human use" sticker is a legal shield for the seller, not a quality signal for you.

The 2026 GLP-1 move is worth understanding because it shows how the system actually works. For a while, when brand-name GLP-1 drugs were in shortage, compounding pharmacies could legally make their own versions. Once the shortages resolved and approved supply caught up, the FDA's view shifted: if an approved drug is available, there's usually no "clinical need" to compound it from bulk powder. That's the logic behind closing the compounding door. The lesson generalizes — compounding access tends to be tied to shortage and clinical need, not to a peptide being good or popular.

Comparisons and alternatives

If your goal is weight loss, the approved GLP-1 and dual-agonist peptides are the strongest tools available, full stop. No unapproved peptide comes close to their trial evidence.

If your goal is recovery or joint health, there is no approved peptide for healthy people. The honest alternatives are the unglamorous ones: physical therapy, progressive loading, sleep, and protein intake — all of which have better evidence than BPC-157 in humans.

If your goal is anti-aging or body composition, be skeptical. Tesamorelin is approved only for HIV lipodystrophy, and the secretagogues marketed for this lack strong human data.

Safety and what to watch for

Even approved peptides carry real risks. GLP-1 drugs commonly cause nausea and can drive muscle loss along with fat. Tesamorelin can affect blood sugar and fluid retention. Bremelanotide commonly causes nausea and can raise blood pressure.

For unapproved peptides, the bigger risk is the unknown. No purity guarantee, no dosing standard, no long-term safety data. "It's natural, it's just a peptide" is not a safety argument — insulin is a peptide, and the wrong dose can kill you.

There's also a sterility problem people overlook. Injectable peptides are meant to be sterile. Gray-market vials reconstituted at home with non-sterile water, or stored wrong, can introduce infection at the injection site. That risk has nothing to do with whether the peptide itself "works" — it's about how it's made and handled.

Red flags worth treating as deal-breakers: a vendor selling injectables labeled "not for human use," a clinic promising results no trial has ever shown, a product claiming to be both "all natural" and dramatically effective, and anyone telling you an unapproved peptide is "basically FDA approved." It either is or it isn't. If a seller can't name the exact FDA-approved indication and brand, assume there isn't one.

Who this is for

Approved peptides like the GLP-1s make sense for people who meet the medical criteria — diabetes or obesity — and who'll use them under a prescriber. Tesamorelin and bremelanotide fit narrow groups defined by their approvals.

The unapproved peptides are, at best, an experiment you run on yourself with no safety net. Some people accept that. If you do, go in clear-eyed: the evidence is mostly from animals, the products are inconsistent, and "approved" is a word that doesn't apply.

For deeper dives, see our guides on where to buy peptides legally, the difference between compounded peptides and research chemicals, the BPC-157 and TB-500 evidence, the full peptide legality picture, and how to vet peptide vendor quality.

Frequently Asked Questions

Is BPC-157 FDA approved?

No. BPC-157 has never been approved by the FDA for any use. Most of the evidence behind its healing claims comes from animal and lab studies, not controlled human trials. It was flagged as a Category 2 substance over safety concerns in 2023, and while the regulatory status kept shifting through 2026, none of that adds up to approval.

How many peptides has the FDA approved?

Roughly 100 distinct peptide drugs have been approved since insulin entered medicine in the 1920s. They're spread across many fields — diabetes, cancer, bone health, HIV, and women's health — which is why there's no single tidy "peptide list." Only a handful are the ones consumers usually ask about.

Are semaglutide and tirzepatide peptides?

Yes. Both are peptide drugs that mimic gut hormones controlling appetite and blood sugar. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA approved for type 2 diabetes and weight management, and they have the strongest clinical evidence of any peptides marketed to the public.

Why are unapproved peptides still sold online?

They're sold through pathways that skip full FDA approval. Some come from compounding pharmacies, which have limited oversight. Others are labeled "research chemicals" or "not for human use," which sidesteps purity and safety testing entirely. Neither pathway means the FDA has reviewed the product for safety or effectiveness.

Is tesamorelin approved for anti-aging?

No. Tesamorelin (Egrifta) is FDA approved only to reduce excess abdominal fat in people with HIV-associated lipodystrophy. It's frequently used off-label for anti-aging and body composition, but that use was never studied for approval, and the fat reduction tends to reverse once the drug is stopped.

This article is for educational purposes only and is not medical advice. Talk to a licensed clinician before starting or stopping any peptide or medication.

Sources